Phase II multicenter, randomized, placebo-controlled, double-blind, parallel-group trial of NF-kB decoy oligo DNA in patients with chronic intervertebral disc low back pain

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 11 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

29 Nov 2023 According to Anges media release, the company plan to confirm safety in the first two patients in the Phase I clinical trial in the U.S. (maximum dose 10 mg) to the maximum dose (20 mg) in the Phase II clinical trial in Japan.
29 Nov 2023 According to Anges media release, the Independent Data Safety Monitoring Committee confirmed the safety of two previously administered cases.
26 Oct 2023 According to Anges media release, company signed an agreement with Shionogi & Co. on Mar 20, 2023 regarding cooperation in this Phase II clinical trial.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com